Synopsis
Synopsis
0
JDMF
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Estrone Sulfate
2. Estrone Sulfate, 14c-labeled
3. Estrone Sulfate, 16-(14)c-labeled
4. Estrone Sulfate, Ammonium Salt
5. Estrone Sulfate, Potassium Salt
6. Estrone Sulfate, Sodium Salt
7. Estrone-3-sulfate
8. Evex
9. Oestrone Sulphate
10. Potassium Estrone Sulfate
11. Sodium Estrone Sulfate
1. Sodium Estrone Sulfate
2. Estrone Sodium Sulfate
3. 438-67-5
4. Estrone Sodium Sulphate
5. Estrone 3-sulfate Sodium Salt
6. Conestoral
7. Hyhorin
8. Morestin
9. Estrone Sulfate Sodium
10. Par Estro
11. Estrone Sulfate Sodium Salt
12. Estrone-3-sulfate Sodium Salt
13. Sodium Estrone Sulphate
14. Sodium Estrone 3-sulfate
15. Oestrone-3-sulphate Sodium Salt
16. Estrogenic Substances (conjugated)
17. Estra-1,3,5(10)-trien-17-one, 3-(sulfooxy)-, Sodium Salt
18. 6k6fda543a
19. Chebi:8389
20. 17-oxoestra-1,3,5(10)-trien-3-yl Sodium Sulfate
21. Nsc-18313
22. Estrone Sulfate (sodium)
23. Sodium;[(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] Sulfate
24. Sodium Estrone-3-sulfate
25. 1,3,5(10)-estratrien-3-ol-17-one Sulphate, Sodium Salt
26. Smr000058772
27. Einecs 207-120-4
28. Nsc 18313
29. Unii-6k6fda543a
30. Conjugated Estrogens: Sodium Estrone Sulfate
31. Estrone3-sulfatesodiumsalt
32. Sodium (8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta(a)phenanthren-3-yl Sulfate
33. Sodium (8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6h-cyclopenta[a]phenanthren-3-yl Sulfate
34. Sodium 17-oxoestra-1(10),2,4-trien-3-yl Sulfate
35. Estrone, Hydrogen Sulfate, Sodium Salt
36. Schembl4616
37. Mls000069757
38. Mls001424259
39. Chembl2106240
40. Dtxsid00860005
41. Dtxsid70881181
42. Hms2052j05
43. Hms2232j23
44. Discontinued. See E889070
45. Akos015967195
46. Estrone Sodium Sulfate [vandf]
47. Ccg-101163
48. Hy-113293b
49. Nc00413
50. Estrone Sodium Sulfate [who-dd]
51. Cs-0108249
52. D00312
53. Q4118295
54. Sodium 17-oxoestra-1,3,5(10)-trien-3-yl Sulfate
55. Estrone 3-sulfate Sodium Salt, Stabilized With Tris
56. Estra-1,3,5(10)-trien-17-one 3-(sulfooxy) Sodium Salt
57. Sodium [(8r,9s,13s,14s)-13-methyl-17-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-yl] Sulfate
Molecular Weight | 372.4 g/mol |
---|---|
Molecular Formula | C18H21NaO5S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 372.10073922 g/mol |
Monoisotopic Mass | 372.10073922 g/mol |
Topological Polar Surface Area | 91.9 Ų |
Heavy Atom Count | 25 |
Formal Charge | 0 |
Complexity | 630 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Premarin |
PubMed Health | Conjugated Estrogens (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Musculoskeletal Agent |
Drug Label | Premarin Intravenous (conjugated estrogens, USP) for injection contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average com... |
Active Ingredient | Estrogens, conjugated |
Dosage Form | Tablet; Cream; Injectable |
Route | oral; Injection; Oral; Topical, vaginal |
Strength | 25mg/vial; 0.45mg; 1.25mg; 0.625mg/gm; 0.625mg; 0.9mg; 0.3mg |
Market Status | Prescription |
Company | Wyeth Pharms |
2 of 2 | |
---|---|
Drug Name | Premarin |
PubMed Health | Conjugated Estrogens (By mouth) |
Drug Classes | Endocrine-Metabolic Agent, Musculoskeletal Agent |
Drug Label | Premarin Intravenous (conjugated estrogens, USP) for injection contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average com... |
Active Ingredient | Estrogens, conjugated |
Dosage Form | Tablet; Cream; Injectable |
Route | oral; Injection; Oral; Topical, vaginal |
Strength | 25mg/vial; 0.45mg; 1.25mg; 0.625mg/gm; 0.625mg; 0.9mg; 0.3mg |
Market Status | Prescription |
Company | Wyeth Pharms |
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Conjugated Estrogens manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Conjugated Estrogens, including repackagers and relabelers. The FDA regulates Conjugated Estrogens manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Conjugated Estrogens API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Conjugated Estrogens manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Conjugated Estrogens supplier is an individual or a company that provides Conjugated Estrogens active pharmaceutical ingredient (API) or Conjugated Estrogens finished formulations upon request. The Conjugated Estrogens suppliers may include Conjugated Estrogens API manufacturers, exporters, distributors and traders.
click here to find a list of Conjugated Estrogens suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Conjugated Estrogens DMF (Drug Master File) is a document detailing the whole manufacturing process of Conjugated Estrogens active pharmaceutical ingredient (API) in detail. Different forms of Conjugated Estrogens DMFs exist exist since differing nations have different regulations, such as Conjugated Estrogens USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Conjugated Estrogens DMF submitted to regulatory agencies in the US is known as a USDMF. Conjugated Estrogens USDMF includes data on Conjugated Estrogens's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Conjugated Estrogens USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Conjugated Estrogens suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Conjugated Estrogens Drug Master File in Korea (Conjugated Estrogens KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Conjugated Estrogens. The MFDS reviews the Conjugated Estrogens KDMF as part of the drug registration process and uses the information provided in the Conjugated Estrogens KDMF to evaluate the safety and efficacy of the drug.
After submitting a Conjugated Estrogens KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Conjugated Estrogens API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Conjugated Estrogens suppliers with KDMF on PharmaCompass.
A Conjugated Estrogens CEP of the European Pharmacopoeia monograph is often referred to as a Conjugated Estrogens Certificate of Suitability (COS). The purpose of a Conjugated Estrogens CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Conjugated Estrogens EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Conjugated Estrogens to their clients by showing that a Conjugated Estrogens CEP has been issued for it. The manufacturer submits a Conjugated Estrogens CEP (COS) as part of the market authorization procedure, and it takes on the role of a Conjugated Estrogens CEP holder for the record. Additionally, the data presented in the Conjugated Estrogens CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Conjugated Estrogens DMF.
A Conjugated Estrogens CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Conjugated Estrogens CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Conjugated Estrogens suppliers with CEP (COS) on PharmaCompass.
A Conjugated Estrogens written confirmation (Conjugated Estrogens WC) is an official document issued by a regulatory agency to a Conjugated Estrogens manufacturer, verifying that the manufacturing facility of a Conjugated Estrogens active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Conjugated Estrogens APIs or Conjugated Estrogens finished pharmaceutical products to another nation, regulatory agencies frequently require a Conjugated Estrogens WC (written confirmation) as part of the regulatory process.
click here to find a list of Conjugated Estrogens suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Conjugated Estrogens as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Conjugated Estrogens API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Conjugated Estrogens as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Conjugated Estrogens and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Conjugated Estrogens NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Conjugated Estrogens suppliers with NDC on PharmaCompass.
Conjugated Estrogens Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Conjugated Estrogens GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Conjugated Estrogens GMP manufacturer or Conjugated Estrogens GMP API supplier for your needs.
A Conjugated Estrogens CoA (Certificate of Analysis) is a formal document that attests to Conjugated Estrogens's compliance with Conjugated Estrogens specifications and serves as a tool for batch-level quality control.
Conjugated Estrogens CoA mostly includes findings from lab analyses of a specific batch. For each Conjugated Estrogens CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Conjugated Estrogens may be tested according to a variety of international standards, such as European Pharmacopoeia (Conjugated Estrogens EP), Conjugated Estrogens JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Conjugated Estrogens USP).
LOOKING FOR A SUPPLIER?